Last reviewed · How we verify
Placebo males
Placebo produces no pharmacological effect, serving as an inert control in clinical trials to measure the placebo response.
Placebo produces no pharmacological effect, serving as an inert control in clinical trials to measure the placebo response. Used for Clinical trial control arm (not a therapeutic indication).
At a glance
| Generic name | Placebo males |
|---|---|
| Also known as | saline physiological 5 ml |
| Sponsor | Ullevaal University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inactive substance administered in controlled clinical studies to establish baseline efficacy and safety by comparison with active drug. Any observed clinical benefit from placebo is attributed to psychological factors, natural disease progression, or regression to the mean rather than direct pharmacological action. Placebos are essential for blinded trial design to isolate true drug effects from expectancy and observer bias.
Approved indications
- Clinical trial control arm (not a therapeutic indication)
Common side effects
- Placebo response (perceived symptom improvement without active drug)
Key clinical trials
- The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguing Exercise in 18-45-year-old Male and Female Participants. (NA)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance (NA)
- Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects (PHASE1)
- Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) (PHASE2)
- A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
- A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) (PHASE2)
- A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo males CI brief — competitive landscape report
- Placebo males updates RSS · CI watch RSS
- Ullevaal University Hospital portfolio CI